JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1995; 26:313-318
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurfinkel, E.
Right arrow Articles by Mautner, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurfinkel, E.
Right arrow Articles by Mautner, B

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

EP Gurfinkel, EJ Manos, RI Mejail, MA Cerda, EA Duronto, CN Garcia, AM Daroca, and B Mautner

Institute of Cardiology and Cardiovascular Surgery, Favaloro Foundation, Buenos Aires, Argentina.

OBJECTIVES. This study was designed to test the hypothesis that low molecular weight heparin may lessen the severity of ischemic events in patients with unstable angina. BACKGROUND. Unstable angina is a thrombotic process that requires intensive medical treatment. Although current treatments can reduce the number of complications, serious bleeding continues to occur. Nadroparin calcium, a low molecular weight heparin, seems to be a safe therapeutic agent that does not require laboratory monitoring. METHODS. A total of 219 patients with unstable angina entered the study at a mean time of 6.17 h after the last episode of rest pain. Patients were randomized to receive aspirin (200 mg/day [group A]), aspirin plus regular heparin (400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time [group B]) and aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously [group C]). The major end points determined for the in-hospital period were 1) recurrent angina, 2) myocardial infarction, 3) urgent revascularization, 4) major bleeding, and 5) death. Minor end points were 1) silent myocardial ischemia, and 2) minor bleeding. Event rates were tested by chi-square analysis. RESULTS. Recurrent angina occurred in 37%, 44% and 21% of patients in groups A, B and C, respectively, and was significantly less frequent in group C than in either group A (odds ratio 2.26, 95% confidence interval [CI] 1 to 5.18, p = 0.03) or group B (odds ratio, 3.07, 95% CI 1.36 to 7.00, p = 0.002). Nonfatal myocardial infarction was present in seven patients in group A, four in group B and none in group C (group B vs. A, p = 0.5; group C vs. A, p = 0.01). Urgent revascularization was performed in nine patients in group A, seven in group B and one in group C (C vs. A, p = 0.01). Two episodes of major bleeding occurred in group B. Silent myocardial ischemia was present in 38%, 41% and 25% of patients in groups A, B and C, respectively, and was significantly less frequent in group C than group B (odds ratio 2.12, 95% CI 0.97 to 4.69, p = 0.04). Minor bleeding was detected in 10 patients in group B, 1 patient in group C (B vs. C, p = 0.01) and no patient in group A (A vs. B, p = 0.003). CONCLUSIONS. In this study, treatment with aspirin plus a high dose of low molecular weight heparin during the acute phase of unstable angina was significantly better than treatment with aspirin alone or aspirin plus regular heparin.


This article has been cited by other articles:


Home page
ChestHome page
R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman
Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 670S - 707S.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660.
[Full Text] [PDF]


Home page
CirculationHome page
K. P. Alexander, L. K. Newby, C. P. Cannon, P. W. Armstrong, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al.
Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Circulation, May 15, 2007; 115(19): 2549 - 2569.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
M. H. Ellis, R. Hadari, N. Tchuvrero, S. Shapira, I. Kovlenko, M. Kozmiakova, R. Zissin, and A. Elis
Hemorrhagic Complications in Patients Treated with Anticoagulant Doses of a Low Molecular Weight Heparin (Enoxaparin) in Routine Hospital Practice
Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 199 - 204.
[Abstract] [PDF]


Home page
CirculationHome page
Part 8: Stabilization of the Patient With Acute Coronary Syndromes
Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110.
[Full Text] [PDF]


Home page
CirculationHome page
Part 5: Acute Coronary Syndromes
Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
L. R Moser and J. S Kalus
Role of Low-Molecular-Weight Heparin in Invasive Management of Non-ST-Elevation Acute Coronary Syndromes
Ann. Pharmacother., December 1, 2004; 38(12): 2094 - 2104.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman
Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 287S - 310S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
R. A. Harrington, R. C. Becker, M. Ezekowitz, T. W. Meade, C. M. O'Connor, D. A. Vorchheimer, and G. H. Guyatt
Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 513S - 548S.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Montalescot, J.P. Collet, M.L. Tanguy, A. Ankri, L. Payot, R. Dumaine, R. Choussat, F. Beygui, V. Gallois, and D. Thomas
Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin
Circulation, July 27, 2004; 110(4): 392 - 398.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. P. Gurfinkel, R. Leon de la Fuente, O. Mendiz, and B. Mautner
Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study: One-year follow-up
Eur. Heart J., January 1, 2004; 25(1): 25 - 31.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
E. H. Kincaid, M. L. Monroe, D. L. Saliba, N. D. Kon, W. G. Byerly, and M. G. Reichert
Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting
Ann. Thorac. Surg., July 1, 2003; 76(1): 124 - 128.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Altman, H. L. Luciardi, J. Muntaner, F. Del Rio, S. G. Berman, R. Lopez, and C. Gonzalez
Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation: The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study
Circulation, July 9, 2002; 106(2): 191 - 195.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
W. Ageno and A. G.G. Turpie
New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins
Can. Med. Assoc. J., April 1, 2002; 166(7): 919 - 924.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
J. Schweizer, A. Muller, L. Forkmann, G. Hellner, and W. Kirch
Potential Use of a Low-Molecular-Weight Heparin to Prevent Restenosis in Patients with Extensive Wall Damage Following Peripheral Angioplasty
Angiology, October 1, 2001; 52(10): 659 - 669.
[Abstract] [PDF]


Home page
CirculationHome page
A. M. Ross, P. Molhoek, C. Lundergan, M. Knudtson, Y. Draoui, L. Regalado, V. Le Louer, F. Bigonzi, W. Schwartz, E. de Jong, et al.
Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II)
Circulation, August 7, 2001; 104(6): 648 - 652.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Auer, R. Berent, and B. Eber
Comparison of low-molecular weight heparins to unfractionated heparin
Eur. Heart J., August 1, 2001; 22(15): 1359 - 1359.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster
Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21 (7): e9 - e9.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
A. G. G. Turpie and E. M. Antman
Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes
Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster
Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Circulation, June 19, 2001; 103(24): 2994 - 3018.
[Full Text] [PDF]


Home page
CMAJHome page
D. Fitchett, S. Goodman, and A. Langer
New advances in the management of acute coronary syndromes: 1. Matching treatment to risk
Can. Med. Assoc. J., May 1, 2001; 164(9): 1309 - 1316.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
G. N. Levine, M. N. Ali, and A. I. Schafer
Antithrombotic Therapy in Patients With Acute Coronary Syndromes
Arch Intern Med, April 9, 2001; 161(7): 937 - 948.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
F. De Lorenzo, A. Noorani, and V.V. Kakkar
Current trends in the management of thromboembolic events
QJM, April 1, 2001; 94(4): 179 - 185.
[Full Text] [PDF]


Home page
ChestHome page
J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Chest, January 1, 2001; 119(1_suppl): 64S - 94S.
[Full Text] [PDF]


Home page
ChestHome page
M. N. Levine, G. Raskob, S. Landefeld, and C. Kearon
Hemorrhagic Complications of Anticoagulant Treatment
Chest, January 1, 2001; 119(1_suppl): 108S - 121S.
[Full Text] [PDF]


Home page
ChestHome page
J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade
Antithrombotic Agents in Coronary Artery Disease
Chest, January 1, 2001; 119(1_suppl): 228S - 252S.
[Full Text] [PDF]


Home page
Vasc MedHome page
W. Ageno and A. G. Turpie
Therapy of unstable angina with the low molecular weight heparins
Vascular Medicine, November 1, 2000; 5(4): 217 - 223.
[Abstract] [PDF]


Home page
Vasc MedHome page
G. G Nenci and A. Minciotti
Low molecular weight heparins for arterial thrombosis
Vascular Medicine, November 1, 2000; 5(4): 251 - 258.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. G. Goodman, A. Barr, A. Sobtchouk, M. Cohen, G. J. Fromell, L. Laperriere, C. Hill, A. Langer, and for the Canadian Efficacy and Safety of Subcutaneo
Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy
J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1507 - 1513.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. G. Goodman, M. Cohen, F. Bigonzi, E. P. Gurfinkel, D. R. Radley, V. Le Iouer, G. J. Fromell, C. Demers, A. G. G. Turpie, R. M. Califf, et al.
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the essence study
J. Am. Coll. Cardiol., September 1, 2000; 36(3): 693 - 698.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al.
ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina)
J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kaul and P. K. Shah
Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1699 - 1712.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
Y. Yeghiazarians, J. B. Braunstein, A. Askari, and P. H. Stone
Unstable Angina Pectoris
N. Engl. J. Med., January 13, 2000; 342(2): 101 - 114.
[Full Text] [PDF]


Home page
Emerg. Med. J.Home page
K. Richell-Herren and K. Mackway-Jones
Immediate anticoagulant management of unstable angina
Emerg. Med. J., January 1, 2000; 17(1): 49 - 49.
[Full Text]


Home page
ChestHome page
T. O. Cheng
Low-Molecular-Weight Heparin for Unstable Angina
Chest, December 1, 1999; 116(6): 1833 - 1833.
[Full Text] [PDF]


Home page
Eur Heart JHome page
The Frax.I.S. Study Group
Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)
Eur. Heart J., November 1, 1999; 20(21): 1553 - 1562.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
P. J. Zed, J. E. Tisdale, and S. Borzak
Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes
Arch Intern Med, September 13, 1999; 159(16): 1849 - 1857.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. M. Bates and J. I. Weitz
Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin
Cardiovasc Res, February 1, 1999; 41(2): 418 - 432.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Hirsh
Low-Molecular-Weight Heparin : A Review of the Results of Recent Studies of the Treatment of Venous Thromboembolism and Unstable Angina
Circulation, October 13, 1998; 98(15): 1575 - 1582.
[Full Text] [PDF]


Home page
CirculationHome page
E. M. Antman and R. Handin
Low-Molecular-Weight Heparins : An Intriguing New Twist With Profound Implications
Circulation, July 28, 1998; 98(4): 287 - 289.
[Full Text] [PDF]


Home page
NEJMHome page
The Platelet Receptor Inhibition in Ischemic Syndr
A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina
N. Engl. J. Med., May 21, 1998; 338(21): 1498 - 1505.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Levi, R. J.G. Peters, and H. R. Buller
Weight watching in cardiology: low molecular weight heparin for acute coronary syndromes
Cardiovasc Res, March 1, 1998; 37(3): 564 - 566.
[Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
R. Altman
Controversies in Antithrombotic Therapy in Cardiovascular Diseases
Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24.
[Abstract] [PDF]


Home page
NEJMHome page
J. I. Weitz
Low-Molecular-Weight Heparins
N. Engl. J. Med., September 4, 1997; 337(10): 688 - 699.
[Full Text] [PDF]


Home page
NEJMHome page
M. Cohen, C. Demers, E. P. Gurfinkel, A. G.G. Turpie, G. J. Fromell, S. Goodman, A. Langer, R. M. Califf, K. A.A. Fox, J. Premmereur, et al.
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
N. Engl. J. Med., August 14, 1997; 337(7): 447 - 452.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. W. Armstrong
Heparin in Acute Coronary Disease -- Requiem for a Heavyweight?
N. Engl. J. Med., August 14, 1997; 337(7): 492 - 494.
[Full Text]


Home page
CirculationHome page
W. Klein, A. Buchwald, S. E. Hillis, S. Monrad, G. Sanz, A. G. G. Turpie, J. van der Meer, E. Olaisson, S. Undeland, and K. Ludwig
Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease : Fragmin in Unstable Coronary Artery Disease Study (FRIC)
Circulation, July 1, 1997; 96(1): 61 - 68.
[Abstract] [Full Text]


Home page
NEJMHome page
R. Collins, R. Peto, C. Baigent, and P. Sleight
Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction
N. Engl. J. Med., March 20, 1997; 336(12): 847 - 860.
[Full Text] [PDF]


Home page
CirculationHome page
J. A. Cairns, J. Gill, B. Morton, R. Roberts, M. Gent, J. Hirsh, D. Holder, K. Finnie, J. F. Marquis, S. Naqvi, et al.
Fish Oils and Low-Molecular-Weight Heparin for the Reduction of Restenosis After Percutaneous Transluminal Coronary Angioplasty: The EMPAR Study
Circulation, October 1, 1996; 94(7): 1553 - 1560.
[Abstract] [Full Text]


Home page
Journal Watch CardiologyHome page
LMW Heparin for Unstable Angina?
Journal Watch Cardiology, September 1, 1995; 1995(901): 20 - 20.
[Full Text]


Home page
JWatch GeneralHome page
LMW HEPARIN: SUPERIOR FOR UNSTABLE ANGINA?
Journal Watch (General), August 4, 1995; 1995(804): 2 - 2.
[Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.